Agilent Technologies, Inc.(A) Stock Research - Grey Stern Research

Agilent Technologies, Inc. (A) Stock Analysis

$137.87 (-1.66%)

A Financial Performance


Use the table below to view Agilent Technologies, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $137.87 -
52 Week Low $124.16 -
52 Week High $155.35 -
Market Cap $39.6 Billion 3/10
Gross Margin 100% 1/10
Profit Margin 21% 6/10
EBITDA margin 24% 3/10
Q3 - 2024 Revenue $1.7 Billion 3/10
Q3 - 2024 Earnings $351.0 Million 4/10
Q3 - 2024 Free Cash Flow $0 Million 10/10
Trailing 4 Quarters Revenue $6.5 Billion 3/10
Trailing 4 Quarters Earnings $1.3 Billion 3/10
Quarterly Earnings Growth -26% 8/10
Annual Earnings Growth 60% 2/10
Quarterly Revenue Growth 1% 4/10
Annual Revenue Growth -3% 6/10
Cash On Hand $1.3 Billion 3/10
Short Term Debt $45.0 Million 6/10
Long Term Debt $3.3 Billion 3/10

Agilent Technologies, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Agilent Technologies, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 30.73 6/10
PS 6.09 6/10
PB 6.72 4/10
PC 29.81 7/10
Liabilities to Equity 1.01 7/10
ROA 0.11 4/10
ROE 0.22 6/10
Current Ratio 1.99 2/10
Quick Ratio 0.22 3/10
Long Term Debt to Equity 0.57 4/10
Debt to Equity 0.57 5/10
Burn Rate -6.45 10/10
Cash to Cap 0.03 4/10
CCR 10/10
EV to EBITDA 102.14 7/10
EV to Revenue 6.40 6/10

Company Details

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

CEO: Mr. Michael McMullen

Website: https://www.agilent.com

Address: 5301 Stevens Creek Blvd Santa Clara, CALIFORNIA

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

Agilent Technologies, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Agilent Technologies, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Danaher Corporation DHR $164.6 Billion
Thermo Fisher Scientific Inc. TMO $199.2 Billion
Illumina, Inc. ILMN $22.2 Billion
IDEXX Laboratories, Inc. IDXX $35.0 Billion
Waters Corporation WAT $22.6 Billion
Charles River Laboratories International, Inc. CRL $9.8 Billion
Mettler-Toledo International Inc. MTD $26.3 Billion
Invitae Corporation NVTA $5.4 Million
Guardant Health, Inc. GH $4.6 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
A Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 1.7 Billion $351.0 Million
Q3 2024 $ 1.6 Billion $282.0 Million
Q2 2024 $ 1.6 Billion $308.0 Million
Q1 2024 $ 1.7 Billion $348.0 Million
Q4 2023 $ 1.7 Billion $475.0 Million
Q3 2023 $ 1.7 Billion $111.0 Million
Q2 2023 $ 1.7 Billion $302.0 Million
Q1 2023 $ 1.8 Billion $352.0 Million

View All

A Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $1.3 Billion $11.8 Billion $3.4 Billion $5.9 Billion
Q3 2024 $1.8 Billion $11.0 Billion $2.9 Billion $5.9 Billion
Q2 2024 $1.7 Billion $10.9 Billion $2.6 Billion $6.2 Billion
Q1 2024 $1.7 Billion $10.9 Billion $2.6 Billion $6.2 Billion
Q4 2023 $1.6 Billion $10.8 Billion $2.7 Billion $5.8 Billion
Q3 2023 $1.3 Billion $10.7 Billion $2.8 Billion $5.6 Billion
Q2 2023 $1.2 Billion $10.8 Billion $2.7 Billion $5.8 Billion
Q1 2023 $1.3 Billion $10.9 Billion $3.0 Billion $5.6 Billion

View All

A Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $360.0 Million -$92.0 Million $108.0 Million
Q2 2024 $230.0 Million -$103.0 Million -$77.0 Million
Q1 2024 $485.0 Million $0 $157.0 Million
Q4 2023 $502.0 Million $0 $502.0 Million
Q3 2023 $481.0 Million -$81.0 Million $154.0 Million
Q2 2023 $341.0 Million -$57.0 Million -$75.0 Million
Q1 2023 $220.0 Million -$76.0 Million $197.0 Million
Q4 2022 $378.0 Million -$70.0 Million -$17.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions